Table 1. Baseline Characteristics of Enrolled Participants.
| Characteristic | Value | Range |
|---|---|---|
| Total Patients (N=23) | ||
| Age at enrollment, mean (SD), y | 62.4 (12.5) | 35-78 |
| Male sex, No. (%) | 15 (65) | |
| Hispanic ethnicity, No. (%) | 3 (13) | |
| Riluzole use, No. (%) | 15 (65) | |
| No. of cramps per 24 h | 7 (7) | 1-25 |
| Cramp severity, unita | 43 (23) | 8-95 |
| Fasciculation severity, unita | 32 (26) | 0-100 |
| Patients From Both Phases (n=20) | ||
| Age at enrollment, mean (SD), y | 62.6 (13.2) | 35-78 |
| Disease duration, mean (SD), mo | 33.6 (27.5) | 4-118 |
| ALSFRS-R score, mean (SD) | 33.2 (9.3) | 12-45 |
| Male sex, No. (%) | 14 (70) | |
| Hispanic ethnicity, No. (%) | 5 (25) | |
| No. of cramps per 24 h | 6 (6) | 1-24 |
| Cramp severity, unita | 46 (23) | 16-95 |
| Fasciculation severity, unita | 34 (26) | 0-100 |
| ALS diagnosis | ||
| Definitive | 11 (55) | |
| Probable | 6 (30) | |
| Possible | 3 (15) | |
Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale–Revised.
a
Severity rated on the 100-unit visual analog scale.